Although unable to
reach consensus on a number of issues, the working group produced 5 recommendations. The working group offers 2 recommendations addressing the criteria necessary to determine when genetic results JQEZ5 mouse should and may be returned to study participants, respectively. In addition, it suggests that a time limit be established to limit the duration of obligation of investigators to return genetic research results. The group recommends the creation of a central body, or bodies, to provide guidance on when genetic research results are associated with sufficient risk and have established clinical utility to justify their return to study participants. The final recommendation urges investigators to engage the broader community when dealing with identifiable communities to advise them on the return of aggregate
and individual research results. Creation of an entity charged to provide guidance to institutional review boards, investigators, research institutions, and research sponsors would provide rigorous review of available data, promote standardization of study policies regarding return of genetic research results, and enable investigators and study participants to clarify and share expectations for the handling of this increasingly valuable information with appropriate respect for the rights and needs of participants. (Circ Cardiovasc Genet. 2010;3:574-580.)”
“Objective: PS-095760 To examine the prevalence and correlates of substance use during pregnancy among women in the United States.
Methods: We analyzed data from pregnant (n = 1800) and non-pregnant women (n = 37,527) aged
15-44 years who participated in the 2002 or 2003 National Survey on Drug Use and Health, a nationally representative epidemiologic Survey. Study variables included demographics, any Substance use in the prior 30 days, and possible current psychopathology. Data were analyzed using weighted chi-square and multiple logistic regressions that accounted for the complex survey design.
Results: The overall prevalence of any past month substance use during pregnancy was 25.8%; the prevalence rates of past month illicit Selleck VS-6063 drug, cigarette and alcohol use were 4.7%, 18.9%, and 10%, respectively. Compared to the prevalence of substance use among Women in their first trimester, use Was Significantly lower among women in their second or third trimesters. Women who reported using Substances during pregnancy were significantly more likely to meet the criteria for possible current psychopathology and be White. Additionally, women who were employed, married, and in their second or third trimester compared to the first were significantly less likely to have used any Substance during pregnancy, adjusting for age, ethnicity and income.